Attention deficit hyperactivity disorder in adults. Attention-deficit hyperactivity disorder, unspecified type
Conditions
Interventions
Intervention 1: Intervention group 1: Pharmacotherapy with methylphenidate 10 milligram immediate release tablets ( Ritalin) manufactured by Novartis pharmaceutical industry in Switzerland. The medici
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
19 Years to 50 Years
Inclusion criteria
Inclusion criteria: Attention Deficit Hyperactivity Disorder Age between 19-50 years Signing consent form
Exclusion criteria
Exclusion criteria: Patients with a history of any systemic disorder such as cardiovascular diseases Patients with a history of bipolar disorder, major depressive disorder, psychosis, substance abuse, pervasive developmental disorder and intellectual disability Using psychotropic drugs within one month prior to the initiation of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score of inattentive and hyperactive symptoms in Conners Adult ADHD Rating Scale - self report questionnaire. Timepoint: Before intervention and 2, 4, 6 and 8 weeks after the intervention. Method of measurement: Self report Conners Adult ADHD Rating Scale questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| The score of Hamilton Depression questionnaire. Timepoint: Before intervention and 8 weeks after the intervention. Method of measurement: Hamilton depression questionnaire.;The score of Hamilton Anxiety questionnaire. Timepoint: Before intervention and 8 weeks after the intervention. Method of measurement: Hamilton Anxiety questionnaire.;The score of general assessment of functioning scale. Timepoint: Before intervention and 8 weeks after the intervention. Method of measurement: General assessment of functioning scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParya Tajmehrabi Namini
Tehran University of Medical Sciences
Outcome results
None listed